Anastrozole-induced autoimmune hepatitis: A rare complication of breast cancer therapy

9Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Background: Autoimmune hepatitis (AIH) is an extremely rare complication of anastrozole therapy. It presents with elevated liver function tests. The diagnosis is established by detecting high titers of autoantibodies such as antinuclear antibodies, anti-smooth muscle antibodies, and elevated immunoglobulins. It is confirmed with a liver biopsy showing interface rosetting and an increased number of plasma cells. Early diagnosis of anastrozole-induced AIH is important because it allows anastrozole to be discontinued and immunomodulatory treatment to be promptly initiated. Case Report: We present the case of a 71-year-old female patient diagnosed with early-stage breast cancer. The patient developed AIH as a result of treatment with anastrozole. Its clinicopathological presentation, diagnosis, and treatment are reviewed. Conclusion: This case report intends to make clinicians aware of this rare complication of anastrozole therapy. AIH should be suspected in any patient on anastrozole (and possibly, other aromatase inhibitors) who develops elevated liver function tests.

Cite

CITATION STYLE

APA

Klapko, O., Ghoulam, E., Jakate, S., Eswaran, S., & Usha, L. (2017). Anastrozole-induced autoimmune hepatitis: A rare complication of breast cancer therapy. Anticancer Research, 37(8), 4173–4176. https://doi.org/10.21873/anticanres.11805

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free